Figure S8 from Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950

Okano, Fumiyoshi; Saito, Takanori; Minamida, Yoshitaka; Kobayashi, Shinichi; Ido, Takayoshi; Miyauchi, Yasushi; Wasai, Ukei; Akazawa, Daisuke; Kume, Masahiko; Ishibashi, Masaki; Jiang, Ke; Aicher, Alexandra; Heeschen, Christopher; Yonehara, Tetsu

doi:10.1158/2767-9764.22651588.v1

Figure S8 from Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950

journal contribution

posted on 2023-04-18, 13:20 authored by Fumiyoshi Okano, Takanori Saito, Yoshitaka Minamida, Shinichi Kobayashi, Takayoshi Ido, Yasushi Miyauchi, Ukei Wasai, Daisuke Akazawa, Masahiko Kume, Masaki Ishibashi, Ke Jiang, Alexandra Aicher, Christopher Heeschen, Tetsu Yonehara

Mechanism of the TRK-950 antitumor effect in mouse model

Funding

Toray Industries (Toray Industries, Inc.)

History

ARTICLE ABSTRACT

Antibody-based cancer therapies have been demonstrated to be effective, but are only approved for a limited number of targets, because the majority of these markers is shared with healthy tissue, which may result in adverse effects. Here, we have successfully identified CAPRIN-1 as a novel truly cancer-specific target, universally expressed on membranes of various cancer cells including cancer stem cells. Clinical studies are underway for the anti-CAPRIN-1 therapeutic antibody TRK-950.